Suchergebnisse - "Buisseret, Laurence"

PubPharm (41)

1

Spatial transcriptomics reveals substantial heterogeneity in triple negative breast cancer with potential clinical implications

enthalten in: ResearchSquare.com | 2024

von Wang, X. | Venet, D. | Lifrange, F. | +19

2

Microtubule targeting agents influence the clinical benefit of immune response in early breast cancer

enthalten in: bioRxiv.org | 2024

von Jose, V. | Venet, D. | Rothé, F. | +9

3

Author Correction : Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

enthalten in: Nature communications | 2023

von Buisseret, L. | Loirat, D. | Aftimos, P. | +33

ErratumFor: Nat Commun. 2023 Nov 2;14(1):7018. - PMID 37919269

4

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer : results of the safety run-in phase of the Neo-CheckRay trial

enthalten in: Journal for immunotherapy of cancer | 2023

von De Caluwe, A. | Romano, E. | Poortmans, P. | +18

5

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Joaquin Garcia, A. | Rediti, M. | Venet, D. | +13

6

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer : the randomized SYNERGY phase I/II trial

enthalten in: Nature communications | 2023

von Buisseret, L. | Loirat, D. | Aftimos, P. | +33

ErratumIn: Nat Commun. 2023 Dec 12;14(1):8223. - PMID 38086864

7

Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma

enthalten in: Cell reports. Medicine | 2023

von Allard, B. | Jacoberger-Foissac, C. | Cousineau, I. | +9

8

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer

enthalten in: Cold Spring Harbor molecular case studies | 2023

von Amato, O. | Buisseret, L. | Gebhart, G. | +5

9

Immunotherapy in breast cancer : an overview of current strategies and perspectives

enthalten in: NPJ breast cancer | 2023

von De Caluwé, A. | Wang, X. | Piccart-Gebhart, M. | +3

10

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer : Promises and Challenges

enthalten in: Journal of clinical medicine | 2023

von Wang, X. | Collet, L. | Rediti, M. | +7

1
2
3
4
5
Nächster »
[5]